Interview
a16z Podcast | The Science Of Extending Life
- The field of geroscience has shifted from conceptual description to mechanistic intervention, distinguishing between "life extension" (immortality) and "health span extension" (delaying disability and age-related diseases).
- Recent breakthroughs in mammalian models have validated specific interventions that delay disease onset:
- Rapamycin treatment in mice delayed every age-related phenotype and extended lifespan by approximately 30%.
- Clearance of senescent cells (senolytics) in mice boosted lifespan by 30% in recent high-impact studies from the Mayo Clinic and Buck Institute.
- Parabiosis (infusing young blood plasma into older animals) has been shown to revert some aging phenotypes, suggesting circulating factors suppress or promote youthfulness.
- Research methodologies have accelerated through the development of genomic biomarkers that measure "biological age" rather than chronological age, allowing scientists to assess drug efficacy within years rather than decades.
- Data infrastructure is being leveraged via large-scale biobanks with integrated electronic health records to predict longevity outcomes based on blood-based metabolites and transcriptomes.
- Regulatory pathways are currently undergoing a fundamental shift to accommodate prevention-based therapies:
- The FDA is reviewing the TAME (Targeting Aging with Metformin) trial, which tests whether the diabetes drug metformin can delay the onset of age-related diseases in healthy patients.
- Historical constraints requiring drugs to be "safe as water" for healthy populations are being relaxed as the concept of treating aging as a primary risk factor gains traction.
- Pharmaceutical companies are expected to initially target specific disease indications (e.g., Alzheimer's, cardiovascular disease) to gain approval before broadening to general aging prevention.
- Future therapeutics will likely include multiple modalities:
- Small-molecule drugs (e.g., rapalogs, senolytics) which can be delivered as pills and eventually become inexpensive generics.
- Protein or antibody-based therapies (e.g., plasma infusions, neutralizing antibodies) which are more invasive but address specific circulating aging factors.
- BioAge, a company led by CEO Kristen Fortney, is actively researching these biomarkers and interventions, with ongoing trials exploring plasma infusions for early-onset Alzheimer's.
- Economic and societal implications include:
- Potential massive public cost savings, incentivizing government support similar to preventative measures like seat belts or fluoride.
- Significant demographic shifts, including extended fertility windows, prolonged workforce participation, and delayed retirement ages.
- Equity challenges regarding access, where initial therapies might be restricted to the wealthy until patents expire and insurance coverage evolves.
- Experts emphasize that extending life by 10–40 years without extending disability remains the primary goal, noting that population growth is unlikely due to concurrent declining fertility rates in developed nations.